Table 3.
The diagnostic utility of the change in VAFmean or tumor makers
| mRECIST | diagnostic ability PR/CR | |||||||
|---|---|---|---|---|---|---|---|---|
| PD | SD | PR/CR | specificity | sensitivity | PPV | NPV | ||
| VAFmean | increase | 4 | 2 | 0 | ||||
| decrease | 0 | 3 | 14 | 0.67 | 1.0 | 0.82 | 1.0 | |
| AFP (all cases) | increase | 1 | 0 | 1 | ||||
| decrease | 3 | 6 | 13 | 0.10 | 0.93 | 0.59 | 0.50 | |
| AFP (≥20 ng/mL at baseline) | increase | 0 | 0 | 0 | ||||
| decrease | 2 | 1 | 8 | 0 | 1.0 | 0.73 | – | |
| DCP (all cases) | increase | 4 | 5 | 10 | ||||
| decrease | 0 | 1 | 4 | 0.90 | 0.29 | 0.80 | 0.47 | |
| DCP (≥40mAU/mL at baseline) | increase | 4 | 4 | 6 | ||||
| decrease | 0 | 1 | 3 | 0.89 | 0.33 | 0.75 | 0.47 | |
mRECIST modified Response Evaluation Criteria in Solid Tumors, AFP α-fetoprotein, DCP des-gamma-carboxy pro-thrombin, VAF variant allele frequency, PD progressve disease, SD stable disease, PR partial response, CR complete response, PPV positive predictive value, NPV negative predictive value